The Hong Kong Exchanges and Clearing (HKEX) added the clinical-stage firm to its benchmark index following recent methodology updates designed to capture emerging AI value chains. This inclusion is poised to increase trading liquidity and draw capital from Mainland Chinese investors via Southbound Stock Connect, further cementing the company's position among major tech-focused portfolios.
In section Releases
Insilico Medicine Joins HKEX Tech 100 Index
With a 287% revenue surge in the first half of 2026, Insilico Medicine has secured a spot in the HKEX Tech 100 Index. The inclusion, effective September 14, signals a shift in market sentiment toward generative AI-driven drug discovery as the company transitions into its first profitable year since listing.
Insilico's financial momentum mirrors its operational output. The company reported an adjusted net profit exceeding $51 million for the first half of 2026, bolstered by high-value collaborations with partners including Eli Lilly, Servier, and Takeda. Total contract value for deals announced this year has reached approximately $7.3 billion. Beyond the balance sheet, the firm set a record in pipeline productivity by nominating nine development candidates in nine months, led by Rentosertib, the world's first generative AI-discovered drug now in Phase III trials for idiopathic pulmonary fibrosis.
Comments (0)
No comments yet. Be the first!